Effects of statin therapy on diagnoses of new-onset diabetes and worsening glycaemia in large-scale randomised blinded statin trials: an individual participant data meta-analysis
Christina Reith(University of Oxford), Jackie Bosch(Universität Ulm), Ian C. Marschner(The University of Sydney), Helen M. Colhoun(Edinburgh Cancer Research), J. Wouter Jukema(Leiden University Medical Center), Anthony Keech(Heidelberg University), Philip J. Barter(The Heart Research Institute), Jordan Fulcher, Elizabeth H Barnes, Salim Yusuf(Population Health Research Institute), Charlie Harper, Enti Spata(Medical Research Council), Pierre Amarenco(Assistance Publique – Hôpitaux de Paris), Wolfgang Köenig(German Centre for Cardiovascular Research), Luigi Tavazzi(Maria Cecilia Hospital), Marc S. Sabatine(Brigham and Women's Hospital), Colin Baigent(University of Oxford), Jonathan Emberson(University of Oxford), Heather Halls, Shinya Goto(Tokai University), David Preiss(Medical Research Council), Robert Clarke(Nuffield Health), Kate Wilson(The University of Sydney), Connie B. Newman(New York University), Lisa Holland, Harvey D. White(University of Auckland), Michael A. Blazing, G. A. Hitman, Gregory G. Schwartz(University of Colorado Denver), Lisa Blackwell(University of Oxford), Borislava Mihaylova(Queen Mary University of London), John Simes(The University of Sydney), William G. Herrington(Oxford Health NHS Foundation Trust), Naveed Sattar(University of Glasgow), Christopher P. Cannon(Nuffield Health), Alistair Roddick, Paul N. Durrington(University of Manchester), Adrienne Kirby(Heidelberg University), Stella Trompet, Paul M. Ridker(Herlev Hospital), Kelly Davies, Jeffrey L Probsfield, Gerard J Blauw, Jane Armitage(Nuffield Health), Andrew Tonkin(Monash University), Rory Collins(University of Oxford), G. Kees Hovingh(Academic Medical Center), Hiroyuki Arashi(Tokyo Women's Medical University), D. J. Betteridge, Rachel O’Connell(Royal Marsden NHS Foundation Trust)
Cited by 148
Related Papers
Dabigatran versus Warfarin in Patients with Atrial Fibrillation
|New England Journal of Medicine|2009|11.2k
Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease
|New England Journal of Medicine|2017|9.1k
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
|New England Journal of Medicine|2019|6.8k
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
|New England Journal of Medicine|2018|6.3k
Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease
|New England Journal of Medicine|2017|6k